{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T19:59:53Z","timestamp":1791316793020,"version":"4.3.1"},"reference-count":30,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,4,28]],"date-time":"2021-04-28T00:00:00Z","timestamp":1619568000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009947","name":"Merck Sharp and Dohme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009947","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003399","name":"Science and Technology Commission of Shanghai Municipality","doi-asserted-by":"publisher","award":["18DZ1910700"],"award-info":[{"award-number":["18DZ1910700"]}],"id":[{"id":"10.13039\/501100003399","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003399","name":"Science and Technology Commission of Shanghai Municipality","doi-asserted-by":"publisher","award":["18DZ1910702"],"award-info":[{"award-number":["18DZ1910702"]}],"id":[{"id":"10.13039\/501100003399","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jto.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thoracic Oncology"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1016\/j.jtho.2021.04.001","type":"journal-article","created":{"date-parts":[[2021,4,26]],"date-time":"2021-04-26T01:55:04Z","timestamp":1619402104000},"page":"1403-1414","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":52,"title":["Efficacy and Safety of Niraparib as Maintenance Treatment in Patients With Extensive-Stage SCLC After First-Line Chemotherapy: A Randomized, Double-Blind, Phase 3 Study"],"prefix":"10.1016","volume":"16","author":[{"given":"Xinghao","family":"Ai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yueyin","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianhua","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunling","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianying","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaodong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaorong","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianxing","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoling","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gongyan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingya","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wangjun","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiping","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiyong","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liyan","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiuwei","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunhong","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cuimin","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohua","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beili","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoqing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianping","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anwen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junling","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhe","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinyin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengzhao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Biao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shun","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtho.2021.04.001_bib1","doi-asserted-by":"crossref","first-page":"129","DOI":"10.21147\/j.issn.1000-9604.2020.02.01","article-title":"Cancer burden and trends in China: a review and comparison with Japan and South Korea","volume":"32","author":"Sun","year":"2020","journal-title":"Chin J Cancer Res"},{"key":"10.1016\/j.jtho.2021.04.001_bib2","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1002\/cncr.29098","article-title":"Small cell lung cancer: where do we go from here?","volume":"121","author":"Byers","year":"2015","journal-title":"Cancer"},{"key":"10.1016\/j.jtho.2021.04.001_bib3","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.15748","article-title":"Comparison of first-line treatments for patients with extensive-stage small cell lung cancer: a systematic review and network meta-analysis","volume":"3","author":"Zhou","year":"2020","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jtho.2021.04.001_bib4","first-page":"26","article-title":"Treatment for small cell lung cancer, where are we now?-a review","volume":"5","author":"Alvarado-Luna","year":"2016","journal-title":"Transl Lung Cancer Res"},{"key":"10.1016\/j.jtho.2021.04.001_bib5","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1634\/theoncologist.2020-0193","article-title":"Prolonging survival: the role of immune checkpoint inhibitors in the treatment of extensive-stage small cell lung cancer","volume":"25","author":"Melosky","year":"2020","journal-title":"Oncologist"},{"key":"10.1016\/j.jtho.2021.04.001_bib6","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.3390\/cancers12092645","article-title":"Adding PD-1\/PD-L1 inhibitors to chemotherapy for the first-line treatment of extensive stage small cell lung cancer (SCLC): a meta-analysis of randomized trials","volume":"12","author":"Facchinetti","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jtho.2021.04.001_bib7","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1007\/s00432-020-03362-z","article-title":"Efficacy and safety of immune checkpoint inhibitors (ICIs) in extensive-stage small cell lung cancer (SCLC)","volume":"147","author":"Ma","year":"2021","journal-title":"J\u00a0Cancer Res Clin Oncol"},{"key":"10.1016\/j.jtho.2021.04.001_bib8","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s11864-018-0568-3","article-title":"Targeted therapy and immune therapy for small cell lung cancer","volume":"19","author":"Gadgeel","year":"2018","journal-title":"Curr Treat Options Oncol"},{"key":"10.1016\/j.jtho.2021.04.001_bib9","doi-asserted-by":"crossref","first-page":"222","DOI":"10.3389\/fonc.2015.00222","article-title":"Successes and challenges of PARP inhibitors in cancer therapy","volume":"5","author":"Ricks","year":"2015","journal-title":"Front Oncol"},{"key":"10.1016\/j.jtho.2021.04.001_bib10","doi-asserted-by":"crossref","first-page":"2512","DOI":"10.1200\/JCO.2009.26.9589","article-title":"Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval","volume":"28","author":"Fong","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2021.04.001_bib11","doi-asserted-by":"crossref","first-page":"6381","DOI":"10.1158\/0008-5472.CAN-09-1178","article-title":"Functional restoration of BRCA2 protein by secondary BRCA2 mutations in BRCA2-mutated ovarian carcinoma","volume":"69","author":"Sakai","year":"2009","journal-title":"Cancer Res"},{"key":"10.1016\/j.jtho.2021.04.001_bib12","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1158\/2159-8290.CD-12-0112","article-title":"Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1","volume":"2","author":"Byers","year":"2012","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jtho.2021.04.001_bib13","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1158\/1078-0432.CCR-16-1040","article-title":"PARP inhibitor activity correlates with SLFN11 expression and demonstrates synergy with temozolomide in small cell lung cancer","volume":"23","author":"Lok","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"suppl 4","key":"10.1016\/j.jtho.2021.04.001_bib14","doi-asserted-by":"crossref","first-page":"S1160","DOI":"10.1016\/j.annonc.2020.08.2259","article-title":"LBA29 Individualized starting dose of niraparib in Chinese patients with platinum-sensitive recurrent ovarian cancer (PSROC): a randomized, double-blind, placebo-controlled, phase III trial (NORA)","volume":"31","author":"Wu","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtho.2021.04.001_bib15","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1093\/annonc\/mdy181","article-title":"Safety and dose modification for patients receiving niraparib","volume":"29","author":"Berek","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtho.2021.04.001_bib16","doi-asserted-by":"crossref","DOI":"10.1634\/theoncologist.2019-0565","article-title":"Phase I pharmacokinetic study of niraparib in Chinese patients with epithelial ovarian cancer","volume":"25","author":"Zhang","year":"2020","journal-title":"Oncologist"},{"key":"10.1016\/j.jtho.2021.04.001_bib17","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1056\/NEJMoa1810858","article-title":"Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer","volume":"379","author":"Moore","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtho.2021.04.001_bib18","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1056\/NEJMoa1910962","article-title":"Niraparib in patients with newly diagnosed advanced ovarian cancer","volume":"381","author":"Gonz\u00e1lez-Mart\u00edn","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtho.2021.04.001_bib19","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1016\/S0140-6736(17)32440-6","article-title":"Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"390","author":"Coleman","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.jtho.2021.04.001_bib20","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1056\/NEJMoa1611310","article-title":"Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer","volume":"375","author":"Mirza","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtho.2021.04.001_bib21","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/S1470-2045(17)30469-2","article-title":"Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"18","author":"Pujade-Lauraine","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtho.2021.04.001_bib22","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa1809064","article-title":"First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer","volume":"379","author":"Horn","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"suppl\u00a05","key":"10.1016\/j.jtho.2021.04.001_bib23","doi-asserted-by":"crossref","first-page":"v710","DOI":"10.1093\/annonc\/mdz264","article-title":"IMpower133: updated\u00a0overall survival (OS) analysis of first-line (1L) atezolizumab (atezo)\u00a0+ carboplatin\u00a0+ etoposide in extensive-stage SCLC (ES-SCLC)","volume":"30","author":"Reck","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtho.2021.04.001_bib24","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1016\/S0140-6736(19)32222-6","article-title":"Durvalumab plus platinum\u2013etoposide versus platinum\u2013etoposide in first-line treatment of extensive-stage small-cell lung cancer (Caspian): a randomised, controlled, open-label, phase 3 trial","volume":"394","author":"Paz-Ares","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.jtho.2021.04.001_bib25","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S1470-2045(20)30539-8","article-title":"Durvalumab, with or without tremelimumab, plus platinum\u2013etoposide versus platinum\u2013etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (Caspian): updated results from a randomised, controlled, open-label, phase 3 trial","volume":"22","author":"Goldman","year":"2021","journal-title":"Lancet Oncol"},{"issue":"suppl 4","key":"10.1016\/j.jtho.2021.04.001_bib26","doi-asserted-by":"crossref","first-page":"S819","DOI":"10.1016\/j.annonc.2020.08.1582","article-title":"1268P JASPER: efficacy and safety of first-line (1L) niraparib plus a programmed death receptor 1 inhibitor (PD-1i) in patients with advanced non-small cell lung cancer (NSCLC)","volume":"31","author":"Ramalingam","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtho.2021.04.001_bib27","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1016\/j.jtho.2019.04.026","article-title":"Durvalumab in combination with olaparib in patients with relapsed SCLC: results from a phase II study","volume":"14","author":"Thomas","year":"2019","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2021.04.001_bib28","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1038\/s41416-020-01202-y","article-title":"The role of Schlafen 11 (SLFN11) as a predictive biomarker for targeting the DNA damage response","volume":"124","author":"Coleman","year":"2021","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jtho.2021.04.001_bib29","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1200\/JCO.2018.77.7672","article-title":"Randomized, double-blind, phase II study of temozolomide in combination with either veliparib or placebo in patients with relapsed-sensitive or refractory small-cell lung cancer","volume":"36","author":"Pietanza","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2021.04.001_bib30","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.ccell.2020.12.014","article-title":"Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities","volume":"39","author":"Gay","year":"2021","journal-title":"Cancer Cell"}],"container-title":["Journal of Thoracic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086421021110?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086421021110?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T10:46:48Z","timestamp":1761562008000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1556086421021110"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8]]},"references-count":30,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["S1556086421021110"],"URL":"https:\/\/doi.org\/10.1016\/j.jtho.2021.04.001","relation":{},"ISSN":["1556-0864"],"issn-type":[{"value":"1556-0864","type":"print"}],"subject":[],"published":{"date-parts":[[2021,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and Safety of Niraparib as Maintenance Treatment in Patients With Extensive-Stage SCLC After First-Line Chemotherapy: A Randomized, Double-Blind, Phase 3 Study","name":"articletitle","label":"Article Title"},{"value":"Journal of Thoracic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtho.2021.04.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 International Association for the Study of Lung Cancer. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}